National Institute for Research of Metabolic and Cardiovascular Diseases
Published January 1, 2024 | Version v1
Journal article Open

Cardio-ankle vascular index for predicting cardiovascular morbimortality and determinants for its progression in the prospective advanced approach to arterial stiffness (TRIPLE-A-Stiffness) study

Authors/Creators

  • 1. Department of Medicine Solna, Karolinska Institutet and Department of Cardiology Karolinska University Hospital, Stockholm, Sweden
  • 2. Inserm U1116, Nancy, France
  • 3. Université de Lorraine, CHRU Nancy, University Hospital of Nancy, France
  • 4. Paris-Descartes University, AP-HP, Diagnosis and Therapeutic Center, Hôtel Dieu, Paris, France
  • 5. Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Kraków, Poland
  • 6. Department of Internal Medicine, Hospital Mutua Terrassa, University of Barcelona, Terrassa, Spain
  • 7. Department of Medical Clinical Pharmacology, University of Debrecen, Hungary
  • 8. Department of Medicine, Section of Geriatric Medicine, University of Verona, Italy
  • 9. Cardiometabolic Centre, Dept. of Angiology, Szent Imre University Teaching Hospital, Budapest, Hungary
  • 10. Primary Care Research Unit of Salamanca (APISAL), Biomedical Research Institute of Salamanca (IBSAL), Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Spain
  • 11. Institute of Cardiology, Centre of Preventive Cardiology, Yerevan, Armenia
  • 12. Department of Internal Medicine and Geriatric Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland
  • 13. Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Centre, Zagreb, Croatia
  • 14. Almazov Federal Medical Research Centre, St-Petersburg, Russia
  • 15. FSBI "Chazov National Medical Research Centre of Cardiology" of the Ministery of Health of the Russian Federation, Moscow, Russia
  • 16. P. Stradins University Hospital, Cardiology Centre, Riga, Latvia
  • 17. Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Department of Medical Sciences, University of Girona, Primary Care Services, Biomedical Research Institute, Institut Català de la Salut, Girona, Spain
  • 18. Institute of Cardiology, Kiev, Ukraine
  • 19. Medical Faculty, University of Belgrade and Cardiovascular Institute, Dedinje, Belgrade, Serbia
  • 20. Government Institution, L.T. Malaya Therapy Institute of the National Academy of Medical Sciences of Ukraine, Kharkov, Ukraine
  • 21. Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan
  • 22. Institut klinicke a experimentalni mediciny
  • 23. Foundation-Medical Research Institutes, Paris, France

Description

Background: The cardio-ankle vascular index (CAVI) measure of arterial stiffness is associated with prevalent cardiovascular risk factors, while its predictive value for cardiovascular events remains to be established. The aim was to determine associations of CAVI with cardiovascular morbimortality (primary outcome) and all-cause mortality (secondary outcome), and to establish the determinants of CAVI progression. Methods: TRIPLE-A-Stiffness, an international multicentre prospective longitudinal study, enrolled >2000 subjects >= 40 years old at 32 centres from 18 European countries. Of these, 1250 subjects (55% women) were followed for a median of 3.82 (2.81-4.69) years. Findings: Unadjusted cumulative incidence rates of outcomes according to CAVI stratification were higher in highest stratum (CAVI > 9). Cox regression with adjustment for age, sex, and cardiovascular risk factors revealed that CAVI was associated with increased cardiovascular morbimortality (HR 1.25 per 1 increase; 95% confidence interval, CI: 1.03-1.51) and all-cause mortality (HR 1.37 per 1 increase; 95% CI: 1.10-1.70) risk in subjects >= 60 years. In ROC analyses, CAVI optimal threshold was 9.25 (c-index 0.598; 0.542-0.654) and 8.30 (c-index 0.565; 0.512-0.618) in subjects >= or <60 years, respectively, to predict increased CV morbimortality. Finally, age, mean arterial blood pressure, anti-diabetic and lipid-lowering treatment were independent predictors of yearly CAVI progression adjusted for baseline CAVI. Interpretation: The present study identified additional value for CAVI to predict outcomes after adjustment for CV risk factors, in particular for subjects >= 60 years. CAVI progression may represent a modifiable risk factor by treatments.

Notes

 AdlS reports support from Sanofi and Viatris. JB reports support from AstraZeneca, Bayer, Elkendi, Hikma, Leurquin, Omron, Organon, Sanofi, and Vivactis. AK reports honoraria for lecturing from Servier, KRKA, and Novartis, and travel support from Servier. PW reports support from Ministry of Health of the Czech Republic, grant nr. NV 19-09-00125, National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, Project No. LX22NPO5104)–Funded by the European Union–Next Generation EU, Servier, and ProMED. The remaining authors have nothing to disclose.

Files

PIIS2352396424001427.pdf

Files (537.1 kB)

Name Size Download all
md5:c627a49d27b77bb859ac0d3367594814
537.1 kB Preview Download

Additional details

Related works

Has metadata
38632024 (PMID)
Is part of
2352-3964 (ISSN)
2352-3964 (ISSN)
References
10.1016/j.ebiom.2024.105107 (DOI)